Riskpilot← Back to searchSign inGet full accessSever Pharma Solutions AB
ABActiveOrg 5564995081Agneslundsvägen 27Manufacture of pharmaceutical preparations · NACE 2120Est. 1994306 employees
Revenue 2024
SEK 712,2M
+12% vs 2023
EBITDA margin
13.4%
+1066% vs 2023
Equity ratio
56.8%
Financial strength
Net profit 2024
SEK 32,3M
+3723% vs 2023
| Revenue | SEK 712,2M | +12% |
| EBITDA | SEK 95,2M | +1066% |
| Net profit | SEK 32,3M | +3723% |
| Total assets | SEK 701,8M | +10% |
| Equity | SEK 398,3M | +9% |
| Employees | 306 | — |
Legal name
Sever Pharma Solutions AB
Org number
5564995081
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
30 november 1994
Share capital
SEK 10 000 000
Employees
306 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att bedriva forskning och utveckling inom området för mediciniska, diagnostiska, farmaceutiska och kemisk-tekniska produkter, att förvärva och upplåta licenser och agenturer inom området, att idka därmed förenlig verksamhet samt att idka finansiell verksamhet, dock ej sådan verksamhet som avses i lag om bankrörelse eller lag om kreditaktiebolag. Bolaget har vidare till föremål för sin verksamhet att äga och förvalta värdepapper samt idka därmed förenlig verksamhet.
Address
Agneslundsvägen 27
Phone
+4640361800
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 440 421 | 477 861 | 609 905 | 633 791 | 712 158 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 37 093 | 48 810 | 44 658 | 8 160 | 95 152 |
| Depreciation & amort. | −16 218 | −16 846 | −22 010 | −26 304 | −24 600 |
| EBIT | 20 875 | 31 964 | 22 648 | −18 144 | 70 552 |
| Net financials | 2 497 | −4 965 | −8 572 | −5 408 | 234 |
| Profit before tax | 16 793 | 16 510 | 14 955 | 3 392 | 41 488 |
| Tax | −3 813 | −3 697 | −2 644 | −2 547 | −9 187 |
| Net profit | 12 980 | 12 813 | 12 311 | 845 | 32 301 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 429 870 | 455 704 | 546 972 | 637 026 | 701 833 |
| Equity | 159 137 | 171 950 | 273 490 | 366 015 | 398 316 |
| Long-term debt | 131 656 | 111 020 | 0 | 0 | 34 300 |
| Short-term debt | 72 314 | 94 271 | 193 734 | 217 313 | 185 434 |
| Total debt | 203 970 | 205 291 | 193 734 | 217 313 | 219 734 |
EBITDA margin
13.4%
This company
15.8%
Market median
-15% vs market
20202024
Equity ratio
56.8%
This company
38.2%
Market median
+49% vs market
20202024
Return on equity
8.1%
This company
18.4%
Market median
-56% vs market
20202024
Net profit margin
4.5%
This company
8.1%
Market median
-44% vs market
20202024
Asset turnover
1.01×
This company
1.12×
Market median
+10% vs market
20202024
Debt / equity
0.76×
This company
0.62×
Market median
+23% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
OC Chief Auditor | Chief Auditor | 2020 |
| Former (2) | ||
ND Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
SJ Chief Auditor | Chief Auditor | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2020 | |
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Former (6) | ||
| Chairman | 2022 – 2025 | |
| Board of Directors | 2020 – 2025 | |
| Board of Directors | 2020 – 2020 | |
| Chairman | 2020 – 2022 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 | |
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sever Pharma Solutions AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils David Segerberg | Chief Executive Officer | 0 companies |
| Ove Christofer Hultén | Chief Auditor | 0 companies |
| Sven Jakob Tenselius | Chief Auditor | 0 companies |
| Jianis Xouri | Board of Directors | 0 companies |
| Kenneth Stokholm | Chairman | 0 companies |
| Sten Jakob Hedén | Board of Directors | 0 companies |
| Claes Stefan Petersson | Deputy Board Member | 0 companies |
| Elsie Annelie Christin Fasth | Board of Directors | 0 companies |
| Fredrik Hultenius | Chairman | 0 companies |
| Bengt Niklas Fredrik Ellerström | Board of Directors | 0 companies |
| Ulla Karin Kristhammar | Board of Directors | 0 companies |
| Hans Schram | Chairman | 0 companies |
| Maria Susanne Nilsson | Board of Directors | 0 companies |
| Christian Frandsen | Board of Directors | 0 companies |